CN104039788A - 吡唑并[3,4-c]吡啶类衍生物、其制备方法及其在医药上的应用 - Google Patents
吡唑并[3,4-c]吡啶类衍生物、其制备方法及其在医药上的应用 Download PDFInfo
- Publication number
- CN104039788A CN104039788A CN201380004979.3A CN201380004979A CN104039788A CN 104039788 A CN104039788 A CN 104039788A CN 201380004979 A CN201380004979 A CN 201380004979A CN 104039788 A CN104039788 A CN 104039788A
- Authority
- CN
- China
- Prior art keywords
- carbonyls
- phenyl
- mmol
- pyrazolos
- morpholine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
- C07D211/76—Oxygen atoms attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims (1)
- PCT国内申请,权利要求书已公开。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201380004979.3A CN104039788B (zh) | 2012-09-18 | 2013-08-29 | 吡唑并[3,4-c]吡啶类衍生物、其制备方法及其在医药上的应用 |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210349492 | 2012-09-18 | ||
CN201210349492.6 | 2012-09-18 | ||
CN2012103494926 | 2012-09-18 | ||
PCT/CN2013/082535 WO2014044113A1 (zh) | 2012-09-18 | 2013-08-29 | 吡唑并[3,4-c]吡啶类衍生物、其制备方法及其在医药上的应用 |
CN201380004979.3A CN104039788B (zh) | 2012-09-18 | 2013-08-29 | 吡唑并[3,4-c]吡啶类衍生物、其制备方法及其在医药上的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104039788A true CN104039788A (zh) | 2014-09-10 |
CN104039788B CN104039788B (zh) | 2015-10-14 |
Family
ID=50340579
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201380004979.3A Expired - Fee Related CN104039788B (zh) | 2012-09-18 | 2013-08-29 | 吡唑并[3,4-c]吡啶类衍生物、其制备方法及其在医药上的应用 |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN104039788B (zh) |
TW (1) | TW201412737A (zh) |
WO (2) | WO2014044107A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109956886A (zh) * | 2017-12-14 | 2019-07-02 | 连云港恒运药业有限公司 | (z)-[(4-甲氧基苯基)亚肼基]氯乙酸乙酯的制备方法 |
CN113214142A (zh) * | 2020-01-21 | 2021-08-06 | 浙江九洲药业股份有限公司 | 一种阿哌沙班的中间体及制备方法 |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015162551A1 (en) * | 2014-04-21 | 2015-10-29 | Mylan Laboratories Ltd | Process for the preparation of apixaban |
WO2016005560A1 (en) * | 2014-07-11 | 2016-01-14 | Laboratorios Lesvi, S.L. | Process for prepararing apixaban |
CN104311574B (zh) * | 2014-09-19 | 2016-04-20 | 广东东阳光药业有限公司 | 含有噻唑的吡唑并哌啶酮类化合物及其组合物及用途 |
CN104311558B (zh) * | 2014-09-19 | 2016-06-01 | 广东东阳光药业有限公司 | 含有环己烷取代基的吡唑并哌啶酮类化合物及其组合物及用途 |
CN104311555B (zh) * | 2014-09-19 | 2016-04-20 | 广东东阳光药业有限公司 | 吡唑并哌啶酮类化合物及其组合物及用途 |
CN104277041B (zh) * | 2014-09-19 | 2016-01-06 | 广东东阳光药业有限公司 | 含取代甲基的芳香环取代基的吡唑并哌啶酮类化合物及其组合物及用途 |
CN104277040B (zh) * | 2014-09-19 | 2016-04-20 | 广东东阳光药业有限公司 | 含有酰基哌嗪酮取代基的吡唑并哌啶酮类化合物及其组合物及用途 |
CN104327074B (zh) * | 2014-09-19 | 2016-01-06 | 广东东阳光药业有限公司 | 含有内酰胺取代基的吡唑并哌啶酮类化合物及其组合物及用途 |
CN104311575B (zh) * | 2014-09-19 | 2016-04-20 | 广东东阳光药业有限公司 | 含有稠环的吡唑并哌啶酮类化合物及其组合物及用途 |
WO2016067308A1 (en) * | 2014-10-28 | 2016-05-06 | Jubilant Generics Limited (Formerly Jubilant Life Sciences Division) | Process for the preparation of apixaban and intermediates thereof |
CN104513239B (zh) * | 2014-12-10 | 2017-08-22 | 沈阳药科大学 | 吡唑并[3,4‑c]吡啶‑7‑酮类化合物及其应用 |
CN105254630A (zh) * | 2015-11-16 | 2016-01-20 | 江苏康缘药业股份有限公司 | 一种阿哌沙班的制备方法 |
WO2024084217A1 (en) * | 2022-10-19 | 2024-04-25 | Kalvista Pharmaceuticals Limited | 3a,4,5,6-tetrahydro-1 h-pyrazolo[3,4-c]pyridin-7(7ah)-one derivatives as factor xiia inhibitors |
CN116375703A (zh) * | 2023-03-29 | 2023-07-04 | 常州制药厂有限公司 | 一种阿哌沙班的合成工艺 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1578660A (zh) * | 2001-09-21 | 2005-02-09 | 百时美施贵宝公司 | 含有内酰胺的化合物及其衍生物作为Xa因子的抑制剂 |
CN101340933A (zh) * | 2005-08-17 | 2009-01-07 | 百时美施贵宝公司 | 具有环糊精的因子xa抑制剂包合配合物 |
CN103242310A (zh) * | 2012-02-10 | 2013-08-14 | 苏州迈泰生物技术有限公司 | 吡唑并吡啶酮类化合物及其在制备抗凝血药物中的用途 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI320039B (en) * | 2001-09-21 | 2010-02-01 | Lactam-containing compounds and derivatives thereof as factor xa inhibitors | |
AU2003273179A1 (en) * | 2002-05-10 | 2003-12-12 | Bristol-Myers Squibb Company | 1,1-disubstituted cycloalkyl derivatives as factor xa inhibitors |
-
2013
- 2013-08-22 WO PCT/CN2013/082020 patent/WO2014044107A1/zh active Application Filing
- 2013-08-29 WO PCT/CN2013/082535 patent/WO2014044113A1/zh active Application Filing
- 2013-08-29 CN CN201380004979.3A patent/CN104039788B/zh not_active Expired - Fee Related
- 2013-09-06 TW TW102132164A patent/TW201412737A/zh unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1578660A (zh) * | 2001-09-21 | 2005-02-09 | 百时美施贵宝公司 | 含有内酰胺的化合物及其衍生物作为Xa因子的抑制剂 |
CN101340933A (zh) * | 2005-08-17 | 2009-01-07 | 百时美施贵宝公司 | 具有环糊精的因子xa抑制剂包合配合物 |
CN103242310A (zh) * | 2012-02-10 | 2013-08-14 | 苏州迈泰生物技术有限公司 | 吡唑并吡啶酮类化合物及其在制备抗凝血药物中的用途 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109956886A (zh) * | 2017-12-14 | 2019-07-02 | 连云港恒运药业有限公司 | (z)-[(4-甲氧基苯基)亚肼基]氯乙酸乙酯的制备方法 |
CN109956886B (zh) * | 2017-12-14 | 2023-03-07 | 连云港恒运药业有限公司 | (z)-[(4-甲氧基苯基)亚肼基]氯乙酸乙酯的制备方法 |
CN113214142A (zh) * | 2020-01-21 | 2021-08-06 | 浙江九洲药业股份有限公司 | 一种阿哌沙班的中间体及制备方法 |
CN113214142B (zh) * | 2020-01-21 | 2024-01-30 | 浙江九洲药业股份有限公司 | 一种阿哌沙班的中间体及制备方法 |
Also Published As
Publication number | Publication date |
---|---|
WO2014044113A1 (zh) | 2014-03-27 |
WO2014044107A1 (zh) | 2014-03-27 |
TW201412737A (zh) | 2014-04-01 |
CN104039788B (zh) | 2015-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104039788A (zh) | 吡唑并[3,4-c]吡啶类衍生物、其制备方法及其在医药上的应用 | |
KR101991327B1 (ko) | 오피오이드 수용체 리간드와 그 용도 및 제조방법 | |
EP3026045B1 (en) | Quinoline derivative | |
EP3083615B1 (en) | Apoptosis signal-regulating kinase inhibitors | |
EP2271341B1 (en) | Specific inhibitors for vascular endothelial growth factor receptors | |
EA030735B1 (ru) | ПРИМЕНЕНИЕ sGC СТИМУЛЯТОРОВ ДЛЯ ЛЕЧЕНИЯ СИСТЕМНОГО СКЛЕРОЗА (SSc) | |
JPWO2011007819A1 (ja) | ラクタムまたはベンゼンスルホンアミド化合物を含有する医薬 | |
EP3214079B1 (en) | Six-membered ring benzo derivatives as dpp-4 inhibitor and use thereof | |
TW201441221A (zh) | 細胞凋亡訊息調節激酶抑制劑 | |
TW200300081A (en) | Pde9 inhibitors for treating cardiovascular disorders | |
KR101987994B1 (ko) | 치환된 이미다조[1,2-a]피리딘-2-일아민 화합물, 및 약학 조성물 및 이의 사용 방법 | |
KR20190026904A (ko) | 비시클릭 헤테로아릴 치환된 화합물 | |
CN103459382B (zh) | 用于抑制pask的杂环化合物 | |
CN104470898A (zh) | 环烷基甲酸类衍生物、其制备方法及其在医药上的应用 | |
CN101484421A (zh) | 作为parp抑制剂的2-氧基苯甲酰胺衍生物 | |
CA3171258A1 (en) | Mdm2 degraders and uses thereof | |
EP3841092B1 (en) | Crystalline form of compound and uses thereof in medicine | |
CN105658641B (zh) | 氮茚‑酰胺类衍生物、其制备方法及其在医药上的应用 | |
EP3072892A1 (en) | Pyridine derivative and medical use thereof | |
CN111630047B (zh) | 含有羧酸基团的苯并氮杂环类化合物及其制备方法和用途 | |
Wise et al. | 1, 3-Dialkyl-4-(iminoarylmethyl)-1H-pyrazol-5-ols. A series of novel potential antipsychotic agents | |
Wang et al. | Based on 2-(difluoromethyl)-1-[4, 6-di (4-morpholinyl)-1, 3, 5-triazin-2-yl]-1H-benzimidazole (ZSTK474), design, synthesis and biological evaluation of novel PI3Kα selective inhibitors | |
EP3575293B1 (en) | Ethanesulfonate salt of n-{5-[(6,7-dimethoxy-4-quinolinyl)oxy]-2-pyridinyl}-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydro-3-quinolinecarboxamide | |
EP3141549A1 (en) | Crystalline form of pemirolast for use in the treatment of inflammations | |
López-Rojas et al. | Synthesis and biological evaluation of anthracene-9, 10 dione derivatives as CK2 inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20180428 Address after: No. 279, Shanghai, Wen Jing Road, Minhang District, Shanghai Co-patentee after: JIANGSU HENGRUI MEDICINE Co.,Ltd. Patentee after: SHANGHAI HENGRUI PHARMACEUTICAL Co.,Ltd. Co-patentee after: SHANGHAI SHENGDI PHARMACEUTICAL Co.,Ltd. Address before: No. 279, Shanghai, Wen Jing Road, Minhang District, Shanghai Co-patentee before: JIANGSU HENGRUI MEDICINE Co.,Ltd. Patentee before: SHANGHAI HENGRUI PHARMACEUTICAL Co.,Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20151014 |